Mahendra Patel, MD
Gastroenterology · Simi Valley, CANPI 1801833561
Payments from drug & device makers
Across 586 payments — averaging $420.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$169K
- Amgen$53K
- Eli Lilly$15K
- AbbVie$6K
- Johnson & Johnson$1K
- Echosens North America, Inc.$338
- plus $3K from 27 others
Across 6 payments — averaging $338.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
What the payments were for
- Travel & lodging$3383%
- Food & beverage$9,56796%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 29 | $169,082 |
| Amgen | 3 | $53,124 |
| Eli Lilly | 1 | $14,500 |
| AbbVie | 360 | $5,742 |
| Johnson & Johnson | 85 | $1,310 |
| Echosens North America, Inc. | 1 | $338 |
| Gilead | 10 | $294 |
| Endogastric Solutions, Inc | 3 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $217 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $202 |
| Regeneron Healthcare Solutions, Inc. | 6 | $156 |
| Nestle Healthcare Nutrition Inc. | 8 | $151 |
| Madrigal Pharmaceuticals | 6 | $133 |
| Phathom Pharmaceuticals, Inc. | 6 | $128 |
| Pfizer | 4 | $107 |
| Sanofi | 4 | $106 |
| Intercept Pharmaceuticals, Inc. | 4 | $101 |
| Evoke Pharma, Inc. | 2 | $94 |
| Merck | 5 | $90 |
| Vivus LLC | 3 | $70 |
| Aimmune Therapeutics, Inc. | 3 | $59 |
| Novo Nordisk | 3 | $55 |
| Redhill Biopharma Inc. | 2 | $54 |
| Ardelyx, Inc. | 2 | $52 |
| QOL Medical, LLC | 2 | $49 |
| Ferring Pharmaceuticals Inc. | 2 | $45 |
| Bristol Myers Squibb | 2 | $35 |
| Capsovision, Inc. | 1 | $32 |
| HEMA Biologics, LLC | 1 | $29 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Fresenius USA Marketing, Inc. | 1 | $21 |
| Concordia Pharmaceuticals Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$246,679 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 13 | $70,372 |
| ZenpepLipase/Protease/Amylase | 17 | $43,540 |
| LinzessLinaclotide | 56 | $39,646 |
| CreonLipase/Protease/Amylase | 22 | $38,398 |
| MounjaroTirzepatide | 16 | $31,343 |
| Mesalamine | 58 | $26,919 |
| VraylarCariprazine Hcl | 23 | $12,635 |
| ErythromycinErythromycin Base | 13 | $10,893 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 113 | $6,570 |
| Clozapine | 25 | $6,131 |
| Dexlansoprazole DrDexlansoprazole | 16 | $4,766 |
| Pantoprazole Sodium | 361 | $3,109 |
| Sucralfate | 19 | $2,615 |
| Cholestyramine LightCholestyramine | 20 | $2,251 |
| Omeprazole | 199 | $2,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Vraylar | $5,742 | $90,679101 claims |
| Aimmune Therapeutics, Inc.Zenpep | $59 | $43,54017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Simi Valley
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
- Brigid BolandSan Diego$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.